Další formáty:
BibTeX
LaTeX
RIS
@inproceedings{718302,
author = {Palčíková, Ivana and Žourková, Alexandra and Valentová, Daria and Hadašová, Eva},
address = {Brno},
booktitle = {Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop},
keywords = {bulimia; CYP2D6; paroxetine},
language = {eng},
location = {Brno},
isbn = {978-80-87041-18-5},
pages = {59-60},
publisher = {Masaryk University Conference Centre, Czech Republic, Brno},
title = {Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity},
year = {2007}
}
TY - JOUR
ID - 718302
AU - Palčíková, Ivana - Žourková, Alexandra - Valentová, Daria - Hadašová, Eva
PY - 2007
TI - Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity
PB - Masaryk University Conference Centre, Czech Republic, Brno
CY - Brno
SN - 9788087041185
KW - bulimia
KW - CYP2D6
KW - paroxetine
N2 - P450 enzymes are oxidase systems. These enzymes oxidize endogenous and exogenous compounds and usually render them less active, preparing them for elimination from the body. More than 40 individual P450 enzymes have been identified. 2D6 play important role in drug metabolism. SSRI (serotonin reuptake inhibitors) therapy is used in bulimia. There are SSRI, especially paroxetine, with a SSRI-inhibiting effect. This fact may lead to a change of phenotype. Phenotyping enables to identify the current activity of the enzyme. The study included patients diagnosed with bulimia. The goal of the study was to evaluate the efficacy of paroxetine treatment in female patients with mental bulimia (MB) while monitoring CYP2D6 activity. Treatment was evaluated on EAT, HAMA, CGI and UKU scales. CYP2D6 activity phenotyping was performed using the dextromethorphan test. The expectation of a significant improvement in poor metabolizers and consequently slower paroxetine degradation was confirmed on the scale for eating behaviour.
ER -
PALČÍKOVÁ, Ivana, Alexandra ŽOURKOVÁ, Daria VALENTOVÁ a Eva HADAŠOVÁ. Mental bulimia , paroxetine treatment and phenotype monitoring of CYP2D6 activity. In \textit{Addiction and Eating Disorders, Neurobiology nad Comorbidities, Workshop}. Brno: Masaryk University Conference Centre, Czech Republic, Brno, 2007, s.~59-60. ISBN~978-80-87041-18-5.
|
